MaxCyte Inc (MXCT) recent activity suggests a positive outlook with the last week’s performance of -8.24%

On Tuesday, MaxCyte Inc (NASDAQ: MXCT) was 3.54% up from the session before settling in for the closing price of $4.52. A 52-week range for MXCT has been $3.16 – $5.29.

A company in the Healthcare sector has jumped its sales by 18.61% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -11.32%. With a float of $97.35 million, this company’s outstanding shares have now reached $105.30 million.

In an organization with 143 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 79.04%, operating margin of -101.56%, and the pretax margin is -78.36%.

MaxCyte Inc (MXCT) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward MaxCyte Inc stocks. The insider ownership of MaxCyte Inc is 7.71%, while institutional ownership is 67.84%. The most recent insider transaction that took place on Jan 13 ’25, was worth 20,272. In this transaction GENERAL COUNSEL of this company sold 4,466 shares at a rate of $4.54, taking the stock ownership to the 41,447 shares. Before that another transaction happened on Dec 26 ’24, when Company’s Director sold 3,000 for $4.01, making the entire transaction worth $12,021. This insider now owns 141,950 shares in total.

MaxCyte Inc (MXCT) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -11.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.99% during the next five years compared to -16.20% drop over the previous five years of trading.

MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators

You can see what MaxCyte Inc (MXCT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.83.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.38 in one year’s time.

Technical Analysis of MaxCyte Inc (MXCT)

Let’s dig in a bit further. During the last 5-days, its volume was 0.73 million. That was better than the volume of 0.7 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 23.64%. Additionally, its Average True Range was 0.29.

During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 74.45%, which indicates a significant increase from 51.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.02% in the past 14 days, which was higher than the 58.26% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $4.12, while its 200-day Moving Average is $4.14. However, in the short run, MaxCyte Inc’s stock first resistance to watch stands at $4.79. Second resistance stands at $4.90. The third major resistance level sits at $5.06. If the price goes on to break the first support level at $4.52, it is likely to go to the next support level at $4.36. The third support level lies at $4.25 if the price breaches the second support level.

MaxCyte Inc (NASDAQ: MXCT) Key Stats

There are 105,711K outstanding shares of the company, which has a market capitalization of 493.66 million. As of now, sales total 41,290 K while income totals -37,920 K. Its latest quarter income was 8,160 K while its last quarter net income were -11,560 K.